Vontobel Holding’s Verrica Pharmaceuticals VRCA Stock Holding History

Vontobel Holding’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,357	Closed	-$78.3K	–	1136
2023 Q2	$78.3K	Buy	+1,357	New	+$82.4K	﹤0.01%	1060

Other funds holding VRCA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vontobel Holding's VRCA Position: Q3 2023 in Review

Vontobel Holding sold out of Verrica Pharmaceuticals (VRCA) in Q3 2023, closing a stake of 1,357 shares — an estimated $78.3K sold.

Vontobel Holding first reported a position in VRCA in Q2 2023 and held it in 1 quarter. The position peaked at $78.3K in Q2 2023. 67 funds tracked by Wall St. Rank hold VRCA as of Q3 2023.

Vontobel Holding reported no remaining Verrica Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Vontobel Holding sold 1,357 Verrica Pharmaceuticals shares in Q3 2023, an estimated $78.3K.
Vontobel Holding first reported a position in Verrica Pharmaceuticals in Q2 2023 and held it in 1 quarter.
Vontobel Holding's Verrica Pharmaceuticals position peaked at $78.3K in Q2 2023.
67 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2023.

Based on Vontobel Holding's 13F filing for Q3 2023, filed 11 Oct 2023.